Latest News about SPRC
Recent news which mentions SPRC
SciSparc To Acquire One Of Top Sellers Of Food Supplements, Cosmetics And Hemp-Based Products On Amazon
September 14, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Friday
September 02, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Tuesday
August 30, 2022
From Benzinga
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
August 25, 2022
From Benzinga
From Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
August 25, 2022
From Benzinga
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
August 24, 2022
From Benzinga
Why Are Psychedelics Stocks Up Today?
August 24, 2022
From InvestorPlace
S&P 500 Edges Higher; Nordstrom Shares Plummet
August 24, 2022
From Benzinga
Why Citi Trends Is Trading Lower By 17%, Here Are 47 Stocks Moving In Wednesday's Mid-Day Session
August 24, 2022
From Benzinga
From Benzinga
From InvestorPlace
Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket
August 17, 2022
From Benzinga
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
August 16, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Monday
August 15, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Friday
August 12, 2022
From Benzinga
SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
August 12, 2022
Tickers
SPRC
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 28, 2022
From Benzinga
From Benzinga
SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome
July 08, 2022
Tickers
SPRC
From Benzinga
SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome
June 30, 2022
Tickers
SPRC
From Benzinga
SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome
June 29, 2022
Tickers
SPRC
From Benzinga
SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray
June 28, 2022
From Benzinga
SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment
June 24, 2022
Tickers
SPRC
From Benzinga
SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder
June 23, 2022
Tickers
SPRC
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.